Cold urticaria (ColdU) or symptomatic dermographism (SD)
JSPRJasper TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for Briquilimab (SC) in Cold urticaria (ColdU) or symptomatic dermographism (SD). The expected timing is based on the latest available company guidance and may change.
05/14/26:- SPOTLIGHT data informed CSU dosing analysis. No CIndU timeline disclosed. 08/14/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.